Pharmaceutical intelligence for Sound Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 1

Recent signals(2)

ClinicalJuly 1, 2026

SPI-1005 Trial for Meniere's Disease Evaluates Safety and Efficacy

A clinical trial is underway to assess the safety and efficacy of SPI-1005 in treating Meniere's disease symptoms.

ClinicalJune 29, 2026

SPI-1005 Trial for Adults with Cochlear Implants Shows Potential for Side Effect Management

The clinical trial aims to assess the safety and tolerability of SPI-1005 in adults receiving cochlear implants, focusing on side effects such as tinnitus and vertigo.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(2)

Clinical

July 1, 2026

SPI-1005 Trial for Meniere's Disease Evaluates Safety and Efficacy

A clinical trial is underway to assess the safety and efficacy of SPI-1005 in treating Meniere's disease symptoms.

ClinicalJune 29, 2026

SPI-1005 Trial for Adults with Cochlear Implants Shows Potential for Side Effect Management

The clinical trial aims to assess the safety and tolerability of SPI-1005 in adults receiving cochlear implants, focusing on side effects such as tinnitus and vertigo.

Competitive activity

No signals indexed for this entity yet.

Assets

SPI-1005 →

Therapeutic areas

Cochlear Implant →

Meniere's Disease →

Otolaryngology →

Indications

Meniere's Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.